• Alaunos Therapeutics released updated preclinical data from diet-induced obesity mouse studies of its oral metabolic candidate ALN1003, with results already presented in the announcement.
• The studies showed improvements in insulin-resistance-related biomarkers, shifts in adipose endocrine signaling, and liver tissue findings consistent with reduced fat accumulation versus controls.
• The company positioned the readout as supportive of continued development in metabolic syndrome and related conditions, including obesity and MASLD, while noting the work was non-GLP and not predictive of human outcomes.
• Cash and cash equivalents were about $0.354 million as of March 31, 2026, with runway into the second quarter of 2026, driving plans to seek additional financing to continue the program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alaunos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605180800PRIMZONEFULLFEED9722082) on May 18, 2026, and is solely responsible for the information contained therein.